

## Publicly Funded High Risk Vaccine Order Form

Fax completed form to Grey Bruce Public Health @ <b>519-376-7782</b> . All information must be filled out for each vaccine ordered.  High risk eligibility criteria based on <b>Publicly Funded Immunization Schedule – June 2022</b> (Table 3).			
Name of Facility, Physician, or Practice:		Requisition ID: (Public Health Use Only)	
Date:	Phone Number:	Fax Number:	
Haemophilus influenzae type b (Act-HIB®)  Client's Name:  DOB (YYYY/MM/DD):  Dose # 1 2 3 (please circle dose required)	Eligibility - ≥ 5 years with: (please check all that apply)  □ Asplenia (functional or anatomic) (1 dose)  □ Bone marrow or solid organ transplant recipients (1 dose)  □ Cochlear implant recipients (pre/post implant) (1 dose)  □ Hematopoietic stem cell transplant (HSCT) recipients (3 doses)		
Date of Last Dose (If Applicable):(YYYY/MM/DD)  * HSCT recipients are eligible for 3 doses. All other eligible conditions receive only 1 dose. See Table 9 of the Publicly Funded Immunization Schedule – June 2022 for vaccine intervals.	<ul> <li>☐ Immunocompromised individuals re</li> <li>☐ Lung transplant (1 dose)</li> <li>☐ Primary antibody deficiencies (1 do</li> </ul>	elated to disease or therapy (1 dose)	
Hepatitis A (Avaxim®/Havrix®)  Client's Name:  DOB (YYYY/MM/DD):  Dose # 1 2 (please circle dose required)  Date of Last Dose (If Applicable):  (YYYY/MM/DD)	Eligibility — ≥ 1 year who meet one or more of the following: (please check all that apply)  □ Intravenous drug use □ Chronic liver disease, including hepatitis B and C □ Men who have sex with men		
Hepatitis B (Recombivax HB®/Engerix®-B)  Client's Name:  DOB (YYYY/MM/DD):  Dose# 1 2 3 4 Booster (please circle dose required)  Date of Last Dose (If Applicable):  (YYYY/MM/DD)  HPV9 (Gardasil 9®)	prevalence for HBV and who may b families (3 doses)  ☐ Household and sexual contacts of c ☐ History of a sexually transmitted dis ☐ Infants born to HBV-positive carrier ☐ premature infants weighing <2, ☐ premature infants weighing ≥2, ☐ Intravenous drug use (3 doses)  ☐ Liver disease (chronic), including he Awaiting liver transplants (2nd and ☐ Men who have sex with men (3 doses)  ☐ Multiple sex partners (3 doses)  ☐ Needle stick injuries in a non-health ☐ On renal dialysis or those with disea (e.g. haemophilia) (2nd and 3rd doses)  Eligibility – Males age 9 years to 26 years (EI	es have immigrated from countries of high e exposed to HBV carriers through their extended hronic carriers and acute cases (3 doses) sease (3 doses) mothers: .000 gms at birth (4 doses) .000 gms at birth & full/post term infants (3 doses) epatitis C (3 doses) 3rd doses only) ses) n care setting (3 doses) asses requiring frequent receipt of blood products	
Client's Name: DOB (YYYY/MM/DD): Dose # 1 2 3 (please circle dose required) Date of Last Dose (If Applicable): (YYYY/MM/DD)  Meningococcal B(Bexsero®) Client's Name:	through 1997 until 2024-12-31) who:  Have sex with men  Eligibility – 2 months to 17 years who meet of expanded to incl those born 2002 through 20	one or more of the following (*Eligibility criteria 006 until 2024-12-31) with:	
DOB (YYYY/MM/DD): Dose # 1 2 3 4 (please circle dose required) Date of Last Dose (If Applicable): (YYYY/MM/DD)	(please check all that apply)  ☐ Acquired complement deficiencies ☐ Asplenia (functional or anatomic) ☐ Cochlear implant recipients (pre/pc ☐ Complement, properdin, factor D o ☐ HIV	ost implant) r primary antibody deficiencies	
Meningococcal-C-ACYW-135 (Menactra, Menveo or Nimenrix)  Client's Name:  DOB (YYYY/MM/DD):  Dose # 1 2 3 4 Booster (please circle dose required)  Date of Last Dose (If Applicable):  (YYYY/MM/DD)	Eligibility – 9 months – 55 years who meet o expanded to incl. those born 1964 through 1 (please check all that apply)  Acquired complement deficiencies  Asplenia (functional or anatomic)  Cochlear implant recipients (pre/po	(e.g., receiving eculizumab) ost implant)	
Meningococcal C-ACYW135 (Menactra, Menveo or Nimenrix) Client's Name: DOB (YYYY/MM/DD): Dose # 1	Eligibility – ≥ 56 years who meet one or more  Acquired complement deficiencies  Asplenia (functional or anatomic)  Cochlear implant recipients (pre/po	ost implant)	

Version Date: July 2024 Page 1 of 2



## Publicly Funded High Risk Vaccine Order Form

Fax completed form to Grey Bruce Public Health @ <b>519-376-7782</b> . All information must be filled out for each vaccine ordered.  High risk eligibility criteria based on <b>Publicly Funded Immunization Schedule – June 2022</b> (Table 3).			
Name of Facility, Physician, or Practice:		Requisition ID: (Public Health Use Only)	
Date:	Phone Number:	Fax Number:	
MMR Client's Name: DOB (YYYY/MM/DD): Dose # 1 2 (please circle dose required) Date of Last Dose (If Applicable): (YYYY/MM/DD)	Eligibility –6-11 months (1 dose) who meet of Will be traveling to areas where dis Note: 2 additional doses are required of Eligibility ≥18 years (as a 2 <sup>nd</sup> dose):  ☐ If they are health care workers ☐ If they are post-secondary student: ☐ If they are planning to travel to are ☐ Based on health care provider's cliritation.	sease is a concern  at ≥1 year of age and at appropriate intervals  s  as where disease is a concern	
Pneumococcal-C-20 (Prevnar 20 <sup>TM</sup> )  Client's Name:  DOB (YYYY/MM/DD):  Dose # 1 2 3 4 (please circle dose required)  Date of Last Dose (If Applicable):  (YYYY/MM/DD)  (YYYY/MM/DD)	age – see age appropriate eligibility chart from Asplenia (anatomical or functional).  Congenital immunodeficiencies involve (humoral) immunity, T-lessystem (properdin or factor D deficed HIV  Hematopoetic stem cell transplant Immunocompromising therapy inconcendent therapy, radiation therapy, anti-rheumatic drugs  Malignant neoplasms including leuded Sickle cell disease or other hemogled Solid organ or islet cell transplant (Chronic cardiac disease Chronic cardiac disease Chronic cerebral spinal fluid leaked Diabetes mellitus  Chronic liver disease, including heped Hepatic chirrhosis due to any cause Chronic respiratory disease, excluding need Chronic neurologic conditions that	A, splenic dysfunction rolving any part of the immune system, incluing B- ymphocyte (cell) mediated immunity, complement ciencies), or phagocytic functions  (HSCT) (recipient) Inding use of long-term corticosteroids, post-organ-transplant therapy, biologic and certain  kemia and lymphoma obinopathies recipient)  patitis B and C e phrotic syndrome ing asthma, excecpt those treated with high-dose may impair clearance of oral secretions of or the aged, chronic care facilities or wards	
IPV, Tdap-IPV, Td-IPV Client's Name:  DOB (YYYY/MM/DD):  Dose # 1 Date of Last Dose (If Applicable):  (YYYY/MM/DD)	where polio virus is known or susp <b>Note:</b> Travellers are eligible to receive o	n series against polio and are travelling to areas ected to be circulating. a single adult lifetime booster dose of IPV- ite vaccine (i.e. IPV, Tdap-IPV or Td-IPV) should be	
Varicella Client's Name:  DOB (YYYY/MM/DD):  Dose # 1 2 (please circle dose required)  Date of Last Dose (If Applicable):  (YYYY/MM/DD)	<ul> <li>□ Susceptible individuals with cystic f</li> <li>□ Household contacts of immunocon</li> <li>□ Susceptible individuals receiving lo</li> </ul>	its given chronic salicylic acid therapy fibrosis	

Version Date: July 2024 Page 2 of 2